23,137 Shares in Cytek Biosciences, Inc. (NASDAQ:CTKB) Acquired by Intech Investment Management LLC

Intech Investment Management LLC bought a new position in shares of Cytek Biosciences, Inc. (NASDAQ:CTKB) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 23,137 shares of the company’s stock, valued at approximately $128,000.

Several other hedge funds and other institutional investors have also modified their holdings of CTKB. Price T Rowe Associates Inc. MD lifted its position in shares of Cytek Biosciences by 13.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 34,665 shares of the company’s stock worth $233,000 after buying an additional 3,987 shares during the period. SG Americas Securities LLC bought a new position in shares of Cytek Biosciences during the 2nd quarter worth approximately $180,000. Bank of New York Mellon Corp lifted its position in shares of Cytek Biosciences by 3.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 804,261 shares of the company’s stock worth $4,488,000 after buying an additional 29,579 shares during the period. SlateStone Wealth LLC bought a new position in shares of Cytek Biosciences during the 2nd quarter worth approximately $70,000. Finally, Allspring Global Investments Holdings LLC bought a new position in shares of Cytek Biosciences during the 2nd quarter worth approximately $140,000. Institutional investors own 69.46% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Piper Sandler lifted their price objective on Cytek Biosciences from $8.00 to $8.50 and gave the company an “overweight” rating in a research report on Monday, November 11th.

Cytek Biosciences Stock Performance

Shares of CTKB opened at $6.47 on Friday. Cytek Biosciences, Inc. has a 52-week low of $4.66 and a 52-week high of $9.87. The company has a market cap of $833.40 million, a price-to-earnings ratio of -80.86 and a beta of 1.46. The stock has a fifty day moving average price of $5.80 and a two-hundred day moving average price of $5.73.

Cytek Biosciences (NASDAQ:CTKB) last released its earnings results on Tuesday, November 5th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Cytek Biosciences had a negative return on equity of 2.58% and a negative net margin of 5.05%. The business had revenue of $51.50 million for the quarter, compared to analyst estimates of $50.63 million. During the same quarter in the prior year, the company posted ($0.03) earnings per share. As a group, research analysts predict that Cytek Biosciences, Inc. will post -0.06 EPS for the current fiscal year.

About Cytek Biosciences

Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.